zurück

Lisocabtagene maraleucel (diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3b (FL3B); ≥ 2 prior therapies)

 

Subject:

  • Active Substance: Lisocabtagene maraleucel
  • Name: Breyanzi®
  • Therapeutic area: Diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)
  • Pharmaceutical company: Bristol-Myers Squibb GmbH

 

Time table:

  • Start: 01.09.2022
  • Publication of assessment: 16.01.2023
  • End of public hearing: 06.02.2023
  • Final decision by G-BA: beginning of April 2023

 

Comparative therapy:

  • A patient-individual therapy depending on the lymphoma subentity, biology of the disease, prior therapies, disease progression and overall health status